During the 43rd J.P. Morgan Annual Healthcare Conference last month, Areteia Therapeutics took centre stage, presenting a ...
New company Areteia Therapeutics launched with up to $350 million in financing and an asthma drug candidate from Knopp Biosciences. That drug, dexpramipexole, previously failed a pivotal test in ...
Areteia Therapeutic’s CEO, Jorge Bartolome, shared his company’s novel and first oral drug development to treat eosinophilic ...
Hosted on MSN8mon
This obesity-drug startup emerged from stealth with $290 million and plans to take on Wegovy and Zepbound(In addition to Metsera, PHP has started a company focused on asthma, called Areteia Therapeutics, and another, Comanche, that’s working on preeclampsia.) Initially, says Meanwell, PHP just ...
During the 43rd J.P. Morgan Annual Healthcare Conference last month, Areteia Therapeutics took centre stage, presenting a detailed review of its achievements in 2024 and outlining its 2025 plans.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback